MedTrace Logo

Dosing of LT4 in Older Individuals

NCT06073665 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2026-02-19

No results posted yet for this study

Summary

Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.

Conditions

Interventions

DRUG

Levothyroxine Sodium

Levothyroxine dose will depend on dose at baseline and randomization group

Sponsors & Collaborators

Principal Investigators

  • Anne R. Cappola, M.D., Sc.M. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2028-04-01
Completion
2028-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06073665 on ClinicalTrials.gov